Diversity and versatility of p38 kinase signalling in health and disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Cuenda, A. & Rousseau, S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta 1773, 1358–1375 (2007).
Wagner, E. F. & Nebreda, A. R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 9, 537–549 (2009).
Cuadrado, A. & Nebreda, A. R. Mechanisms and functions of p38 MAPK signalling. Biochem. J. 429, 403–417 (2010).
Kyriakis, J. M. & Avruch, J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol. Rev. 92, 689–737 (2012).
Hotamisligil, G. S. & Davis, R. J. Cell signaling and stress responses. Cold Spring Harb. Perspect. Biol. 8, a006072 (2016).
Han, J., Wu, J. & Silke, J. An overview of mammalian p38 mitogen-activated protein kinases, central regulators of cell stress and receptor signaling. F1000Res. 9, 653 (2020).
Cuenda, A. & Sanz-Ezquerro, J. J. p38γ and p38δ: from spectators to key physiological players. Trends Biochem. Sci. 42, 431–442 (2017). This extensive review addresses the functions of p38γ and p38δ.
Han, J., Lee, J. D., Bibbs, L. & Ulevitch, R. J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265, 808–811 (1994).
Rouse, J. et al. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 78, 1027–1037 (1994).
Freshney, N. W. et al. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 78, 1039–1049 (1994).
Lee, J. C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739–746 (1994). Together with Han et al. (1994), Rouse et al. (1994) and Freshney et al. (1994), this paper reports the identification of the first mammalian p38 kinase using different experimental systems and approaches.
Sudo, T., Yagasaki, Y., Hama, H., Watanabe, N. & Osada, H. Exip, a new alternative splicing variant of p38α, can induce an earlier onset of apoptosis in HeLa cells. Biochem. Biophys. Res. Commun. 291, 838–843 (2002).
Sanz, V., Arozarena, I. & Crespo, P. Distinct carboxy-termini confer divergent characteristics to the mitogen-activated protein kinase p38α and its splice isoform Mxi2. FEBS Lett. 474, 169–174 (2000).
Eyers, P. A., Craxton, M., Morrice, N., Cohen, P. & Goedert, M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem. Biol. 5, 321–328 (1998).
Gum, R. J. et al. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J. Biol. Chem. 273, 15605–15610 (1998).
Adams, R. H. et al. Essential role of p38α MAP kinase in placental but not embryonic cardiovascular development. Mol. Cell 6, 109–116 (2000).
Mudgett, J. S. et al. Essential role for p38α mitogen-activated protein kinase in placental angiogenesis. Proc. Natl Acad. Sci. USA 97, 10454–10459 (2000). Together with Adams et al. (2000), this paper provides in vivo evidence for a critical role of p38α in the regulation of a process unrelated to the acute stress response.
Beardmore, V. A. et al. Generation and characterization of p38β (MAPK11) gene-targeted mice. Mol. Cell Biol. 25, 10454–104645 (2005).
Greenblatt, M. B. et al. The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J. Clin. Invest. 120, 2457–2473 (2010).
del Barco Barrantes, I., Coya, J. M., Maina, F., Arthur, J. S. & Nebreda, A. R. Genetic analysis of specific and redundant roles for p38α and p38β MAPKs during mouse development. Proc. Natl Acad. Sci. USA 108, 12764–12769 (2011).
Arriazu, E. et al. A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia. Blood Cancer J. 10, 3 (2020).
Warr, N. et al. Gadd45γ and Map3k4 interactions regulate mouse testis determination via p38 MAPK-mediated control of Sry expression. Dev. Cell 23, 1020–1031 (2012).
Llopis, A. et al. The stress-activated protein kinases p38α/β and JNK1/2 cooperate with Chk1 to inhibit mitotic entry upon DNA replication arrest. Cell Cycle 11, 3627–3637 (2012).
Hayakawa, M. et al. Loss of functionally redundant p38 isoforms in T cells enhances regulatory T cell induction. J. Biol. Chem. 292, 1762–1772 (2017).
Escos, A., Risco, A., Alsina-Beauchamp, D. & Cuenda, A. p38γ and p38δ mitogen activated protein kinases (MAPKs), new stars in the MAPK galaxy. Front. Cell Dev. Biol. 4, 31 (2016).
Matesanz, N. et al. p38α blocks brown adipose tissue thermogenesis through p38δ inhibition. PLoS Biol. 16, e2004455 (2018).
Qi, X. et al. p38α antagonizes p38γ activity through c-Jun-dependent ubiquitin–proteasome pathways in regulating Ras transformation and stress response. J. Biol. Chem. 282, 31398–31408 (2007).
Alonso, G., Ambrosino, C., Jones, M. & Nebreda, A. R. Differential activation of p38 mitogen-activated protein kinase isoforms depending on signal strength. J. Biol. Chem. 275, 40641–40648 (2000).
Ge, B. et al. MAPKK-independent activation of p38α mediated by TAB1-dependent autophosphorylation of p38α. Science 295, 1291–1294 (2002). This paper presents evidence for a non-canonical mechanism of p38α activation based on TAB1-induced autophosphorylation.
Tanno, M. et al. Diverse mechanisms of myocardial p38 mitogen-activated protein kinase activation: evidence for MKK-independent activation by a TAB1-associated mechanism contributing to injury during myocardial ischemia. Circ. Res. 93, 254–261 (2003).
DeNicola, G. F. et al. Mechanism and consequence of the autoactivation of p38α mitogen-activated protein kinase promoted by TAB1. Nat. Struct. Mol. Biol. 20, 1182–1190 (2013). This paper provides important structural information on the mechanism by which TAB1 binding triggers p38α autophosphorylation.
De Nicola, G. F. et al. The TAB1–p38α complex aggravates myocardial injury and can be targeted by small molecules. JCI Insight 3, e121144 (2018).
Lanna, A., Henson, S. M., Escors, D. & Akbar, A. N. The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells. Nat. Immunol. 15, 965–972 (2014).
Theivanthiran, B. et al. The E3 ubiquitin ligase Itch inhibits p38α signaling and skin inflammation through the ubiquitylation of Tab1. Sci. Signal. 8, ra22 (2015).
Matesanz, N. et al. MKK6 controls T3-mediated browning of white adipose tissue. Nat. Commun. 8, 856 (2017).
Grimsey, N. J. et al. G protein-coupled receptors activate p38 MAPK via a non-canonical TAB1–TAB2- and TAB1–TAB3-dependent pathway in endothelial cells. J. Biol. Chem. 294, 5867–5878 (2019).
Salvador, J. M. et al. Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat. Immunol. 6, 390–395 (2005). This paper describes an alternative mechanism of p38α activation that involves tyrosine phosphorylation and is specific for T cells.
Mittelstadt, P. R., Yamaguchi, H., Appella, E. & Ashwell, J. D. T cell receptor-mediated activation of p38α by mono-phosphorylation of the activation loop results in altered substrate specificity. J. Biol. Chem. 284, 15469–15474 (2009).
Tomida, T., Takekawa, M. & Saito, H. Oscillation of p38 activity controls efficient pro-inflammatory gene expression. Nat. Commun. 6, 8350 (2015).
Staples, C. J., Owens, D. M., Maier, J. V., Cato, A. C. & Keyse, S. M. Cross-talk between the p38α and JNK MAPK pathways mediated by MAP kinase phosphatase-1 determines cellular sensitivity to UV radiation. J. Biol. Chem. 285, 25928–25940 (2010).
Miura, H., Kondo, Y., Matsuda, M. & Aoki, K. Cell-to-cell heterogeneity in p38-mediated cross-inhibition of JNK causes stochastic cell death. Cell Rep. 24, 2658–2668 (2018).
Ambrosino, C. et al. Negative feedback regulation of MKK6 mRNA stability by p38α mitogen-activated protein kinase. Mol. Cell Biol. 23, 370–381 (2003).
Cheung, P. C., Campbell, D. G., Nebreda, A. R. & Cohen, P. Feedback control of the protein kinase TAK1 by SAPK2a/p38α. EMBO J. 22, 5793–5805 (2003).
Giardino Torchia, M. L. et al. Intensity and duration of TCR signaling is limited by p38 phosphorylation of ZAP-70T293 and destabilization of the signalosome. Proc. Natl Acad. Sci. USA 115, 2174–2179 (2018).
Peregrin, S. et al. Phosphorylation of p38 by GRK2 at the docking groove unveils a novel mechanism for inactivating p38MAPK. Curr. Biol. 16, 2042–2047 (2006).
Salvador, J. M., Mittelstadt, P. R., Belova, G. I., Fornace, A. J. Jr. & Ashwell, J. D. The autoimmune suppressor Gadd45α inhibits the T cell alternative p38 activation pathway. Nat. Immunol. 6, 396–402 (2005).
Wu, Y. H. et al. Tumor suppressor death-associated protein kinase 1 inhibits necroptosis by p38 MAPK activation. Cell Death Dis. 11, 305 (2020).
Pillai, V. B. et al. Acetylation of a conserved lysine residue in the ATP binding pocket of p38 augments its kinase activity during hypertrophy of cardiomyocytes. Mol. Cell Biol. 31, 2349–2363 (2011).
Brichkina, A. et al. Proline isomerisation as a novel regulatory mechanism for p38MAPK activation and functions. Cell Death Differ. 23, 1592–1601 (2016).
Jeong, H. J. et al. Prmt7 promotes myoblast differentiation via methylation of p38MAPK on arginine residue 70. Cell Death Differ. 27, 573–586 (2020).
Liu, M. Y., Hua, W. K., Chen, C. J. & Lin, W. J. The MKK-dependent phosphorylation of p38α is augmented by arginine methylation on Arg49/Arg149 during erythroid differentiation. Int. J. Mol. Sci. 21, 3546 (2020).
Round, J. L. et al. Scaffold protein Dlgh1 coordinates alternative p38 kinase activation, directing T cell receptor signals toward NFAT but not NF-κB transcription factors. Nat. Immunol. 8, 154–161 (2007).
Uhlik, M. T. et al. Rac–MEKK3–MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock. Nat. Cell Biol. 5, 1104–1110 (2003).
Zehorai, E. & Seger, R. Beta-like importins mediate the nuclear translocation of mitogen-activated protein kinases. Mol. Cell Biol. 34, 259–270 (2014).
Weaver, B. P. et al. Non-canonical caspase activity antagonizes p38 MAPK stress-priming function to support development. Dev. Cell 53, 358–369.e6 (2020).
Liu, K. et al. Mutual stabilization between TRIM9 short isoform and MKK6 potentiates p38 signaling to synergistically suppress glioblastoma progression. Cell Rep. 23, 838–851 (2018).
Liu, J. et al. F-box only protein 31 (FBXO31) negatively regulates p38 mitogen-activated protein kinase (MAPK) signaling by mediating lysine 48-linked ubiquitination and degradation of mitogen-activated protein kinase kinase 6 (MKK6). J. Biol. Chem. 289, 21508–21518 (2014).
Zou, X. & Blank, M. Targeting p38 MAP kinase signaling in cancer through post-translational modifications. Cancer Lett. 384, 19–26 (2017).
Diao, Y. et al. Oxidation-induced intramolecular disulfide bond inactivates mitogen-activated protein kinase kinase 6 by inhibiting ATP binding. Proc. Natl Acad. Sci. USA 107, 20974–20979 (2010).
Rasmussen, M. H. et al. miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells. Nat. Commun. 7, 12436 (2016).
Turk, B. E. Manipulation of host signalling pathways by anthrax toxins. Biochem. J. 402, 405–417 (2007).
Mukherjee, S. et al. Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science 312, 1211–1214 (2006).
Paquette, N. et al. Serine/threonine acetylation of TGFβ-activated kinase (TAK1) by Yersinia pestis YopJ inhibits innate immune signaling. Proc. Natl Acad. Sci. USA 109, 12710–12715 (2012).
Pellegrini, E. et al. Structural basis for the subversion of MAP kinase signaling by an intrinsically disordered parasite secreted agonist. Structure 25, 16–26 (2017).
Katz, M., Amit, I. & Yarden, Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim. Biophys. Acta 1773, 1161–1176 (2007).
Faust, D. et al. Differential p38-dependent signalling in response to cellular stress and mitogenic stimulation in fibroblasts. Cell Commun. Signal. 10, 6 (2012).
Sakauchi, C., Wakatsuki, H., Ichijo, H. & Hattori, K. Pleiotropic properties of ASK1. Biochim. Biophys. Acta Gen. Subj. 1861, 3030–3038 (2017).
Matsushita, M., Nakamura, T., Moriizumi, H., Miki, H. & Takekawa, M. Stress-responsive MTK1 SAPKKK serves as a redox sensor that mediates delayed and sustained activation of SAPKs by oxidative stress. Sci. Adv. 6, eaay9778 (2020).
Dolado, I. et al. p38α MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 11, 191–205 (2007).
Coelho, M. A. et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity 47, 1083–1099.e6 (2017).
Rodriguez-Colman, M. J. et al. Interplay between metabolic identities in the intestinal crypt supports stem cell function. Nature 543, 424–427 (2017). This article shows that physiological levels of ROS produced by mitochondrial OXPHOS activate p38α in intestinal stem cells to ensure intestinal crypt homeostasis.
L’Honore, A. et al. The role of Pitx2 and Pitx3 in muscle stem cells gives new insights into p38α MAP kinase and redox regulation of muscle regeneration. eLife 7, e32991 (2018).
Fukawa, T. et al. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia. Nat. Med. 22, 666–671 (2016).
Cheng, C. T. et al. Metabolic stress-induced phosphorylation of KAP1 Ser473 blocks mitochondrial fusion in breast cancer cells. Cancer Res. 76, 5006–5018 (2016).
Geller, S. et al. Tanycytes regulate lipid homeostasis by sensing free fatty acids and signaling to key hypothalamic neuronal populations via FGF21 secretion. Cell Metab. 30, 833–844.e7 (2019).
Sabio, G. & Davis, R. J. TNF and MAP kinase signalling pathways. Semin. Immunol. 26, 237–245 (2014).
Lin, J., Lee, D., Choi, Y. & Lee, S. Y. The scaffold protein RACK1 mediates the RANKL-dependent activation of p38 MAPK in osteoclast precursors. Sci. Signal. 8, ra54 (2015).
Sapkota, G. P. The TGFβ-induced phosphorylation and activation of p38 mitogen-activated protein kinase is mediated by MAP3K4 and MAP3K10 but not TAK1. Open. Biol. 3, 130067 (2013).
Gaestel, M., Kotlyarov, A. & Kracht, M. Targeting innate immunity protein kinase signalling in inflammation. Nat. Rev. Drug Discov. 8, 480–499 (2009).
Arthur, J. S. & Ley, S. C. Mitogen-activated protein kinases in innate immunity. Nat. Rev. Immunol. 13, 679–692 (2013).
Takizawa, H. et al. Pathogen-induced TLR4–TRIF innate immune signaling in hematopoietic stem cells promotes proliferation but reduces competitive fitness. Cell Stem Cell 21, 225–240.e5 (2017).
Lee, W. B. et al. Mincle-mediated translational regulation is required for strong nitric oxide production and inflammation resolution. Nat. Commun. 7, 11322 (2016).
Johnson, R. A., Huong, S. M. & Huang, E. S. Activation of the mitogen-activated protein kinase p38 by human cytomegalovirus infection through two distinct pathways: a novel mechanism for activation of p38. J. Virol. 74, 1158–1167 (2000).
Bouhaddou, M. et al. The global phosphorylation landscape of SARS-CoV-2 infection. Cell 182, 685–712.e19 (2020).
Wagstaff, L. et al. Mechanical cell competition kills cells via induction of lethal p53 levels. Nat. Commun. 7, 11373 (2016).
Hofmann, M. et al. Mechanical pressure-induced phosphorylation of p38 mitogen-activated protein kinase in epithelial cells via Src and protein kinase C. Biochem. Biophys. Res. Commun. 316, 673–679 (2004).
Liu, Z. et al. MAPK-mediated YAP activation controls mechanical-tension-induced pulmonary alveolar regeneration. Cell Rep. 16, 1810–1819 (2016).
Raman, M., Earnest, S., Zhang, K., Zhao, Y. & Cobb, M. H. TAO kinases mediate activation of p38 in response to DNA damage. EMBO J. 26, 2005–2014 (2007).
Colomer, C. et al. IKKα kinase regulates the DNA damage response and drives chemo-resistance in cancer. Mol. Cell 75, 669–682.e5 (2019).
Bent, E. H., Gilbert, L. A. & Hemann, M. T. A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses. Genes Dev. 30, 1811–1821 (2016).
Lu, H. et al. Reciprocal regulation of DUSP9 and DUSP16 expression by HIF1 controls ERK and p38 MAP kinase activity and mediates chemotherapy-induced breast cancer stem cell enrichment. Cancer Res. 78, 4191–4202 (2018).
Trempolec, N., Dave-Coll, N. & Nebreda, A. R. SnapShot: p38 MAPK substrates. Cell 152, 924–924.e1 (2013).
Gaestel, M. MAPK-activated protein kinases (MKs): novel insights and challenges. Front. Cell Dev. Biol. 3, 88 (2015).
Reyskens, K. M. & Arthur, J. S. Emerging roles of the mitogen and stress activated kinases MSK1 and MSK2. Front. Cell Dev. Biol. 4, 56 (2016).
Joshi, S. & Platanias, L. C. Mnk kinase pathway: cellular functions and biological outcomes. World J. Biol. Chem. 5, 321–333 (2014).
Dolado, I. & Nebreda, A. R. Regulation of tumorigenesis by p38α MAP kinase. Top. Curr. 20, 99–128 (2008).
Cannell, I. G. et al. A pleiotropic RNA-binding protein controls distinct cell cycle checkpoints to drive resistance of p53-defective tumors to chemotherapy. Cancer Cell 28, 623–637 (2015).
Gubern, A. et al. The N-terminal phosphorylation of RB by p38 bypasses its inactivation by CDKs and prevents proliferation in cancer cells. Mol. Cell 64, 25–36 (2016).
Muranen, T. et al. ERK and p38 MAPK activities determine sensitivity to PI3K/mTOR inhibition via regulation of MYC and YAP. Cancer Res. 76, 7168–7180 (2016).
Phong, M. S. et al. p38 mitogen-activated protein kinase promotes cell survival in response to DNA damage but is not required for the G2 DNA damage checkpoint in human cancer cells. Mol. Cell Biol. 30, 3816–3826 (2010).
Guil, S., Long, J. C. & Caceres, J. F. hnRNP A1 relocalization to the stress granules reflects a role in the stress response. Mol. Cell Biol. 26, 5744–5758 (2006).
Carbonell, C. et al. Functional network analysis reveals the relevance of SKIIP in the regulation of alternative splicing by p38 SAPK. Cell Rep. 27, 847–859.e6 (2019).
Borisova, M. E. et al. p38–MK2 signaling axis regulates RNA metabolism after UV-light-induced DNA damage. Nat. Commun. 9, 1017 (2018).
Bugai, A. et al. P-TEFb activation by RBM7 shapes a pro-survival transcriptional response to genotoxic stress. Mol. Cell 74, 254–267.e10 (2019).
Li, W. et al. Phosphorylation of LAMP2A by p38 MAPK couples ER stress to chaperone-mediated autophagy. Nat. Commun. 8, 1763 (2017).
Wei, Y. et al. The stress-responsive kinases MAPKAPK2/MAPKAPK3 activate starvation-induced autophagy through Beclin 1 phosphorylation. eLife 4, e05289 (2015).
Slobodnyuk, K. et al. Autophagy-induced senescence is regulated by p38α signaling. Cell Death Dis. 10, 376 (2019).
Hwang, S. et al. Protective and detrimental roles of p38α MAPK in different stages of nonalcoholic fatty liver disease. Hepatology 72, 873–891 (2020).
Soustek, M. S. et al. Inhibition of the ER stress IRE1α inflammatory pathway protects against cell death in mitochondrial complex I mutant cells. Cell Death Dis. 9, 658 (2018).
Yang, Q. et al. Stress induces p38 MAPK-mediated phosphorylation and inhibition of Drosha-dependent cell survival. Mol. Cell 57, 721–734 (2015).
Lin, K. C. et al. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation. Nat. Cell Biol. 19, 996–1002 (2017).
Trempolec, N. et al. Induction of oxidative metabolism by the p38α/MK2 pathway. Sci. Rep. 7, 11367 (2017).
Leestemaker, Y. et al. Proteasome activation by small molecules. Cell Chem. Biol. 24, 725–736.e7 (2017).
Simoes-Sousa, S. et al. The p38α stress kinase suppresses aneuploidy tolerance by inhibiting Hif-1α. Cell Rep. 25, 749–760.e6 (2018).
Canovas, B. et al. Targeting p38α increases DNA damage, chromosome instability, and the anti-tumoral response to taxanes in breast cancer cells. Cancer Cell 33, 1094–1110.e8 (2018). This paper describes a p38α-mediated mechanism that regulates DNA repair in cancer cells, and provides evidence that pharmacological inhibitors of p38α potentiate the cytotoxic effect of taxanes in breast cancer mouse models and patient-derived xenografts.
Herbert, K. et al. BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma. Genes Dev. 33, 310–332 (2019).
Kang, Y. J. et al. Macrophage deletion of p38α partially impairs lipopolysaccharide-induced cellular activation. J. Immunol. 180, 5075–5082 (2008).
Youssif, C. et al. Myeloid p38α signaling promotes intestinal IGF-1 production and inflammation-associated tumorigenesis. EMBO Mol. Med. 10, e8403 (2018).
Zheng, T. et al. Protein kinase p38α signaling in dendritic cells regulates colon inflammation and tumorigenesis. Proc. Natl Acad. Sci. USA 115, E12313–E12322 (2018).
Li, J. et al. Activation of DR3 signaling causes loss of ILC3s and exacerbates intestinal inflammation. Nat. Commun. 10, 3371 (2019).
Petrova, T., Pesic, J., Pardali, K., Gaestel, M. & Arthur, J. S. C. p38 MAPK signalling regulates cytokine production in IL-33 stimulated type 2 innate lymphoid cells. Sci. Rep. 10, 3479 (2020).
Gopfert, C. et al. The p38-MK2/3 module is critical for IL-33-induced signaling and cytokine production in dendritic cells. J. Immunol. 200, 1198–1206 (2018).
McCarthy, P. C. et al. IL-33 regulates cytokine production and neutrophil recruitment via the p38 MAPK-activated kinases MK2/3. Immunol. Cell Biol. 97, 54–71 (2019).
Bhattacharya, S. et al. Role of p38 protein kinase in the ligand-independent ubiquitination and down-regulation of the IFNAR1 chain of type I interferon receptor. J. Biol. Chem. 286, 22069–22076 (2011).
Fuchs, S. Y. Ubiquitination-mediated regulation of interferon responses. Growth Factors 30, 141–148 (2012).
Katlinski, K. V. et al. Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell 31, 194–207 (2017).
Ortiz, A. et al. An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles. Cancer Cell 35, 33–45.e6 (2019).
Gui, J. et al. Activation of p38α stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs. Nat. Cancer 1, 603–619 (2020). This extensive study analyses how p38α signalling in fibroblasts facilitates lung tumour growth.
De Maeyer, R. P. H. et al. Blocking elevated p38 MAPK restores efferocytosis and inflammatory resolution in the elderly. Nat. Immunol. 21, 615–625 (2020). This paper shows that pharmacological inhibition of p38α restores the macrophage-mediated resolution of dermal inflammation in older humans, supporting that p38α inhibitors might be useful to treat particular inflammatory diseases.
Jaco, I. et al. MK2 phosphorylates RIPK1 to prevent TNF-induced cell death. Mol. Cell 66, 698–710.e5 (2017).
Dondelinger, Y. et al. MK2 phosphorylation of RIPK1 regulates TNF-mediated cell death. Nat. Cell Biol. 19, 1237–1247 (2017).
Menon, M. B. et al. p38MAPK/MK2-dependent phosphorylation controls cytotoxic RIPK1 signalling in inflammation and infection. Nat. Cell Biol. 19, 1248–1259 (2017). Together with Jaco et al. (2017) and Dondelinger et al. (2017), this paper demonstrates an important role for the p38/MK2 pathway restraining TNF-induced cell death through the phosphorylation of RIPK1.
Segales, J., Perdiguero, E. & Munoz-Canoves, P. Regulation of muscle stem cell functions: a focus on the p38 MAPK signaling pathway. Front. Cell Dev. Biol. 4, 91 (2016).
Consalvi, S., Brancaccio, A., Dall’Agnese, A., Puri, P. L. & Palacios, D. Praja1 E3 ubiquitin ligase promotes skeletal myogenesis through degradation of EZH2 upon p38α activation. Nat. Commun. 8, 13956 (2017).
Rodriguez-Carballo, E., Gamez, B. & Ventura, F. p38 MAPK signaling in osteoblast differentiation. Front. Cell Dev. Biol. 4, 40 (2016).
Bost, F., Aouadi, M., Caron, L. & Binetruy, B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie 87, 51–56 (2005).
Cao, W. et al. p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene. Mol. Cell Biol. 24, 3057–3067 (2004). This paper describes p38 kinase signalling as a central regulator of thermogenesis in brown adipocytes.
Hattori, K. et al. ASK1 signalling regulates brown and beige adipocyte function. Nat. Commun. 7, 11158 (2016).
Yi, D. et al. Zc3h10 acts as a transcription factor and is phosphorylated to activate the thermogenic program. Cell Rep. 29, 2621–2633.e4 (2019).
Ng, R. et al. miRNA-32 drives brown fat thermogenesis and trans-activates subcutaneous white fat browning in mice. Cell Rep. 19, 1229–1246 (2017).
Quesada-Lopez, T. et al. The lipid sensor GPR120 promotes brown fat activation and FGF21 release from adipocytes. Nat. Commun. 7, 13479 (2016).
Hu, P. et al. p38α/JNK signaling restrains erythropoiesis by suppressing Ezh2-mediated epigenetic silencing of Bim. Nat. Commun. 9, 3518 (2018).
Batlle, R. et al. Regulation of tumor angiogenesis and mesenchymal–endothelial transition by p38α through TGF-β and JNK signaling. Nat. Commun. 10, 3071 (2019).
Oeztuerk-Winder, F. & Ventura, J. J. The many faces of p38 mitogen-activated protein kinase in progenitor/stem cell differentiation. Biochem. J. 445, 1–10 (2012).
Wu, X. et al. CUG-binding protein 1 regulates HSC activation and liver fibrogenesis. Nat. Commun. 7, 13498 (2016).
Choo, M. K., Kraft, S., Missero, C. & Park, J. M. The protein kinase p38α destabilizes p63 to limit epidermal stem cell frequency and tumorigenic potential. Sci. Signal. 11, eaau0727 (2018).
He, D. et al. Gut stem cell aging is driven by mTORC1 via a p38 MAPK–p53 pathway. Nat. Commun. 11, 37 (2020).
Karigane, D. et al. p38α activates purine metabolism to initiate hematopoietic stem/progenitor cell cycling in response to stress. Cell Stem Cell 19, 192–204 (2016).
Ito, K. et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat. Med. 12, 446–451 (2006).
Freund, A., Patil, C. K. & Campisi, J. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J. 30, 1536–1548 (2011).
Alspach, E. et al. p38MAPK plays a crucial role in stromal-mediated tumorigenesis. Cancer Discov. 4, 716–729 (2014).
Herranz, N. et al. mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype. Nat. Cell Biol. 17, 1205–1217 (2015).
Hu, J. H. et al. Activity-dependent isomerization of Kv4.2 by Pin1 regulates cognitive flexibility. Nat. Commun. 11, 1567 (2020).
Liu, K. et al. PI31 is an adaptor protein for proteasome transport in axons and required for synaptic development. Dev. Cell 50, 509–524.e10 (2019).
Lloret, A., Fuchsberger, T., Giraldo, E. & Vina, J. Molecular mechanisms linking amyloid β toxicity and Tau hyperphosphorylation in Alzheimers disease. Free Radic. Biol. Med. 83, 186–191 (2015).
Chen, J. et al. Phosphorylation of Parkin at serine 131 by p38 MAPK promotes mitochondrial dysfunction and neuronal death in mutant A53T α-synuclein model of Parkinson’s disease. Cell Death Dis. 9, 700 (2018).
Ashwell, J. D. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat. Rev. Immunol. 6, 532–540 (2006).
Jun, J. E., Kulhanek, K. R., Chen, H., Chakraborty, A. & Roose, J. P. Alternative ZAP70–p38 signals prime a classical p38 pathway through LAT and SOS to support regulatory T cell differentiation. Sci. Signal. 12, eaao0736 (2019).
Alam, M. S. et al. Counter-regulation of T cell effector function by differentially activated p38. J. Exp. Med. 211, 1257–1270 (2014).
Mace, G., Miaczynska, M., Zerial, M. & Nebreda, A. R. Phosphorylation of EEA1 by p38 MAP kinase regulates μ opioid receptor endocytosis. EMBO J. 24, 3235–3246 (2005).
Biondi, R. M. & Nebreda, A. R. Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem. J. 372, 1–13 (2003).
Zeke, A. et al. Systematic discovery of linear binding motifs targeting an ancient protein interaction surface on MAP kinases. Mol. Syst. Biol. 11, 837 (2015).
Jung, H. et al. Thioredoxin-interacting protein regulates haematopoietic stem cell ageing and rejuvenation by inhibiting p38 kinase activity. Nat. Commun. 7, 13674 (2016).
Joshi, S., Kaur, S., Kroczynska, B. & Platanias, L. C. Mechanisms of mRNA translation of interferon stimulated genes. Cytokine 52, 123–127 (2010).
Maik-Rachline, G., Lifshits, L. & Seger, R. Nuclear P38: roles in physiological and pathological processes and regulation of nuclear translocation. Int. J. Mol. Sci. 21, 6102 (2020).
Thornton, T. M. et al. Inactivation of nuclear GSK3β by Ser389 phosphorylation promotes lymphocyte fitness during DNA double-strand break response. Nat. Commun. 7, 10553 (2016).
Reinhardt, H. C., Aslanian, A. S., Lees, J. A. & Yaffe, M. B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11, 175–189 (2007).
Zhang, Y. et al. PP2AC level determines differential programming of p38–TSC–mTOR signaling and therapeutic response to p38-targeted therapy in colorectal cancer. EBioMedicine 2, 1944–1956 (2015).
Kim, D. H. et al. A conserved p38 MAP kinase pathway in Caenorhabditis elegans innate immunity. Science 297, 623–626 (2002).
Gupta, J. & Nebreda, A. R. Roles of p38α mitogen-activated protein kinase in mouse models of inflammatory diseases and cancer. FEBS J. 282, 1841–1857 (2015).
Rincon, M. & Davis, R. J. Regulation of the immune response by stress-activated protein kinases. Immunol. Rev. 228, 212–224 (2009).
Gurusamy, D. et al. Multi-phenotype CRISPR–Cas9 screen identifies p38 kinase as a target for adoptive immunotherapies. Cancer Cell 37, 818–833.e9 (2020). This paper identifies the p38 kinase pathway as a central regulator of several phenotypes associated with the antitumour efficacy of T cells.
Navarrete, M. et al. Astrocytic p38α MAPK drives NMDA receptor-dependent long-term depression and modulates long-term memory. Nat. Commun. 10, 2968 (2019).
Bolshakov, V. Y. et al. Dual MAP kinase pathways mediate opposing forms of long-term plasticity at CA3–CA1 synapses. Nat. Neurosci. 3, 1107–1112 (2000).
Zhu, J. J., Qin, Y., Zhao, M., Van Aelst, L. & Malinow, R. Ras and Rap control AMPA receptor trafficking during synaptic plasticity. Cell 110, 443–455 (2002).
Chung, S. H. et al. The p38α mitogen-activated protein kinase is a key regulator of myelination and remyelination in the CNS. Cell Death Dis. 6, e1748 (2015).
Haines, J. D., Fragoso, G., Hossain, S., Mushynski, W. E. & Almazan, G. p38 mitogen-activated protein kinase regulates myelination. J. Mol. Neurosci. 35, 23–33 (2008).
Liu, X. et al. BMP7 retards peripheral myelination by activating p38 MAPK in Schwann cells. Sci. Rep. 6, 31049 (2016).
Lin, X., Wang, M., Zhang, J. & Xu, R. p38 MAPK: a potential target of chronic pain. Curr. Med. Chem. 21, 4405–4418 (2014).
Scheltens, P. et al. An exploratory clinical study of p38α kinase inhibition in Alzheimer’s disease. Ann. Clin. Transl. Neurol. 5, 464–473 (2018).
Hensley, K. et al. p38 kinase is activated in the Alzheimer’s disease brain. J. Neurochem. 72, 2053–2058 (1999).
Zhu, X. et al. Activation of MKK6, an upstream activator of p38, in Alzheimer’s disease. J. Neurochem. 79, 311–318 (2001).
Sun, A., Liu, M., Nguyen, X. V. & Bing, G. P38 MAP kinase is activated at early stages in Alzheimer’s disease brain. Exp. Neurol. 183, 394–405 (2003).
Du, Y. et al. MKP-1 reduces Aβ generation and alleviates cognitive impairments in Alzheimer’s disease models. Signal. Transduct. Target. Ther. 4, 58 (2019).
Kheiri, G., Dolatshahi, M., Rahmani, F. & Rezaei, N. Role of p38/MAPKs in Alzheimer’s disease: implications for amyloid β toxicity targeted therapy. Rev. Neurosci. 30, 9–30 (2018).
Lee, J. K. & Kim, N. J. Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer’s disease. Molecules 22, 1287 (2017).
Colie, S. et al. Neuronal p38α mediates synaptic and cognitive dysfunction in an Alzheimer’s mouse model by controlling β-amyloid production. Sci. Rep. 7, 45306 (2017).
Thomas, T. et al. MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammation—relevance in a mouse model of Parkinson’s disease. J. Neurochem. 105, 2039–2052 (2008).
Dewil, M., dela Cruz, V. F., Van Den Bosch, L. & Robberecht, W. Inhibition of p38 mitogen activated protein kinase activation and mutant SOD1(G93A)-induced motor neuron death. Neurobiol. Dis. 26, 332–341 (2007).
Bendotti, C. et al. Activated p38MAPK is a novel component of the intracellular inclusions found in human amyotrophic lateral sclerosis and mutant SOD1 transgenic mice. J. Neuropathol. Exp. Neurol. 63, 113–119 (2004).
Gibbs, K. L. et al. Inhibiting p38 MAPKα rescues axonal retrograde transport defects in a mouse model of ALS. Cell Death Dis. 9, 596 (2018).
Bhinge, A., Namboori, S. C., Zhang, X., VanDongen, A. M. J. & Stanton, L. W. Genetic correction of SOD1 mutant iPSCs reveals ERK and JNK activated AP1 as a driver of neurodegeneration in amyotrophic lateral sclerosis. Stem Cell Rep. 8, 856–869 (2017).
Robson, M. J. et al. p38α MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse. Proc. Natl Acad. Sci. USA 115, E10245–E10254 (2018).
Arabacilar, P. & Marber, M. The case for inhibiting p38 mitogen-activated protein kinase in heart failure. Front. Pharmacol. 6, 102 (2015).
Martin, E. D., Bassi, R. & Marber, M. S. p38 MAPK in cardioprotection—are we there yet? Br. J. Pharmacol. 172, 2101–2113 (2015).
Newby, L. K. et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet 384, 1187–1195 (2014).
O’Donoghue, M. L. et al. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial. JAMA 315, 1591–1599 (2016).
Meng, Q. et al. MMI-0100 inhibits cardiac fibrosis in a mouse model overexpressing cardiac myosin binding protein C. J. Am. Heart Assoc. 6, e006590 (2017).
Wang, Q. et al. Disruption of TAB1/p38α interaction using a cell-permeable peptide limits myocardial ischemia/reperfusion injury. Mol. Ther. 21, 1668–1677 (2013).
Manieri, E. & Sabio, G. Stress kinases in the modulation of metabolism and energy balance. J. Mol. Endocrinol. 55, R11–R22 (2015).
Zhang, S. et al. Metabolic benefits of inhibition of p38α in white adipose tissue in obesity. PLoS Biol. 16, e2004225 (2018).
Berry, D. C. et al. Cellular aging contributes to failure of cold-induced beige adipocyte formation in old mice and humans. Cell Metab. 25, 166–181 (2017).
Zhang, X. et al. Macrophage p38α promotes nutritional steatohepatitis through M1 polarization. J. Hepatol. 71, 163–174 (2019).
Puigserver, P. et al. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARγ coactivator-1. Mol. Cell 8, 971–982 (2001).
Brown, J. L. et al. Protein imbalance in the development of skeletal muscle wasting in tumour-bearing mice. J. Cachexia Sarcopenia Muscle 9, 987–1002 (2018).
Bulavin, D. V. & Fornace, A. J. Jr. p38 MAP kinase’s emerging role as a tumor suppressor. Adv. Cancer Res. 92, 95–118 (2004).
Loesch, M. & Chen, G. The p38 MAPK stress pathway as a tumor suppressor or more? Front. Biosci. 13, 3581–3593 (2008).
Hui, L. et al. p38α suppresses normal and cancer cell proliferation by antagonizing the JNK–c-Jun pathway. Nat. Genet. 39, 741–749 (2007).
Ventura, J. J. et al. p38α MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat. Genet. 39, 750–758 (2007).
Gupta, J. et al. Dual function of p38α MAPK in colon cancer: suppression of colitis-associated tumor initiation but requirement for cancer cell survival. Cancer Cell 25, 484–500 (2014). This study describes pro-tumorigenic and anti-tumorigenic functions of p38α in the same mouse model of cancer depending on the tumorigenesis stage.
Igea, A. & Nebreda, A. R. The stress kinase p38α as a target for cancer therapy. Cancer Res. 75, 3997–4002 (2015). This paper presents an overview of the cell autonomous roles of p38α in cancer cells.
Vitos-Faleato, J. et al. Requirement for epithelial p38α in KRAS-driven lung tumor progression. Proc. Natl Acad. Sci. USA 117, 2588–2596 (2020).
Saad, M. I. et al. ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer. EMBO Mol. Med. 11, e9976 (2019).
Wu, X. et al. Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1–p38 MAP kinase cascade. Proc. Natl Acad. Sci. USA 111, 13870–13875 (2014).
Tichet, M. et al. Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis. Nat. Commun. 6, 6993 (2015).
Anwar, T. et al. p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis. Nat. Commun. 9, 2801 (2018).
Ryu, K. J. et al. p38 stabilizes Snail by suppressing DYRK2-mediated phosphorylation that is required for GSK3β–βTrCP-induced Snail degradation. Cancer Res. 79, 4135–4148 (2019).
Naffa, R. et al. p38 MAPK promotes migration and metastatic activity of BRAF mutant melanoma cells by inducing degradation of PMCA4b. Cells 9, 1209 (2020).
Harper, K. L. et al. Mechanism of early dissemination and metastasis in Her2+ mammary cancer. Nature 540, 588–592 (2016).
Urosevic, J. et al. Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. Nat. Cell Biol. 16, 685–694 (2014).
Gawrzak, S. et al. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. Nat. Cell Biol. 20, 211–221 (2018).
Brichkina, A. et al. p38MAPK builds a hyaluronan cancer niche to drive lung tumorigenesis. Genes Dev. 30, 2623–2636 (2016).
Curtis, M. et al. Fibroblasts mobilize tumor cell glycogen to promote proliferation and metastasis. Cell Metab. 29, 141–155.e9 (2019). This interesting study on the interplay between fibroblasts and cancer cells shows how p38α signalling in fibroblasts can modulate the metabolism of cancer cells.
Suarez-Lopez, L. et al. MK2 contributes to tumor progression by promoting M2 macrophage polarization and tumor angiogenesis. Proc. Natl Acad. Sci. USA 115, E4236–E4244 (2018).
Alam, M. S. et al. Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression. Nat. Med. 21, 1337–1343 (2015).
Zonneville, J. et al. Blockade of p38 kinase impedes the mobilization of protumorigenic myeloid populations to impact breast cancer metastasis. Int. J. Cancer 147, 2279–2292 (2020).
Santoro, V. et al. Role of reactive oxygen species in the abrogation of oxaliplatin activity by cetuximab in colorectal cancer. J. Natl Cancer Inst. 108, djv394 (2016).
Garcia-Cano, J. et al. p38MAPK and chemotherapy: we always need to hear both sides of the story. Front. Cell Dev. Biol. 4, 69 (2016).
Lin, A. et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl Med. 11, eaaw841 (2019).
Pereira, L., Igea, A., Canovas, B., Dolado, I. & Nebreda, A. R. Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK. EMBO Mol. Med. 5, 1759–1774 (2013).
Rudalska, R. et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat. Med. 20, 1138–1146 (2014).
Dietlein, F. et al. A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer. Cell 162, 146–159 (2015).
Lalaoui, N. et al. Targeting p38 or MK2 enhances the anti-leukemic activity of smac-mimetics. Cancer Cell 29, 145–158 (2016). This article shows an interesting cooperation between the inhibitors of p38 or MK2 and Smac-mimetic drugs in leukaemia cells, and paves the way for the discovery of an important link between p38/MK2 and RIPK in the inflammatory response.
Murali, B. et al. Inhibition of the stromal p38MAPK/MK2 pathway limits breast cancer metastases and chemotherapy-induced bone loss. Cancer Res. 78, 5618–5630 (2018).
MacNee, W., Allan, R. J., Jones, I., De Salvo, M. C. & Tan, L. F. Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax 68, 738–745 (2013).
Godl, K. et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl Acad. Sci. USA 100, 15434–15439 (2003).
Jones, D. S., Jenney, A. P., Joughin, B. A., Sorger, P. K. & Lauffenburger, D. A. Inflammatory but not mitogenic contexts prime synovial fibroblasts for compensatory signaling responses to p38 inhibition. Sci. Signal. 11, eaal1601 (2018).
Wang, C. et al. Selective inhibition of the p38α MAPK–MK2 axis inhibits inflammatory cues including inflammasome priming signals. J. Exp. Med. 215, 1315–1325 (2018).
Patnaik, A. et al. A first-in-human phase I study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 dimesylate), in patients with advanced cancer. Clin. Cancer Res. 22, 1095–1102 (2016).
Vergote, I. et al. A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer. Gynecol. Oncol. 156, 23–31 (2020).
Donoghue, C. et al. Optimal linker length for small molecule PROTACs that selectively target p38α and p38β for degradation. Eur. J. Med. Chem. 201, 112451 (2020).
Casadome-Perales, A. et al. Inhibition of p38 MAPK in the brain through nasal administration of p38 inhibitor loaded in chitosan nanocapsules. Nanomedicine 14, 2409–2422 (2019).
Maik-Rachline, G., Zehorai, E., Hanoch, T., Blenis, J. & Seger, R. The nuclear translocation of the kinases p38 and JNK promotes inflammation-induced cancer. Sci. Signal. 11, eaao3428 (2018).
Martinez-Limon, A., Joaquin, M., Caballero, M., Posas, F. & de Nadal, E. The p38 pathway: from biology to cancer therapy. Int. J. Mol. Sci. 21, 1913 (2020).
Gee, M. S. et al. A selective p38α/β MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse. Alzheimers Res. Ther. 12, 45 (2020).
Roy, S. M. et al. Targeting human central nervous system protein kinases: an isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer’s disease mouse models. ACS Chem. Neurosci. 6, 666–680 (2015).
Evans, B. C. et al. MK2 inhibitory peptide delivered in nanopolyplexes prevents vascular graft intimal hyperplasia. Sci. Transl Med. 7, 291ra295 (2015).
Sies, H. & Jones, D. P. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat. Rev. Mol. Cell Biol. 21, 363–383 (2020).
Asih, P. R. et al. Functions of p38 MAP kinases in the central nervous system. Front. Mol. Neurosci. 13, 570586 (2020).
Kuzmanic, A. et al. Changes in the free-energy landscape of p38α MAP kinase through its canonical activation and binding events as studied by enhanced molecular dynamics simulations. eLife 6, e22175 (2017).
Tokunaga, Y., Takeuchi, K., Takahashi, H. & Shimada, I. Allosteric enhancement of MAP kinase p38α’s activity and substrate selectivity by docking interactions. Nat. Struct. Mol. Biol. 21, 704–711 (2014).
Kumar, G. S. et al. Dynamic activation and regulation of the mitogen-activated protein kinase p38. Proc. Natl Acad. Sci. USA 115, 4655–4660 (2018). Together with Kuzmanic et al. (2017) and Tokunaga et al. (2014), this paper provides detailed insights into the mechanism of p38α kinase activation using NMR and molecular modelling.
Haller, V., Nahidino, P., Forster, M. & Laufer, S. A. An updated patent review of p38 MAP kinase inhibitors (2014–2019). Expert Opin. Ther. Pat. 30, 453–466 (2020).
Yang, L. et al. p38α mitogen-activated protein kinase is a druggable target in pancreatic adenocarcinoma. Front. Oncol. 9, 1294 (2019).
Shah, N. G. et al. Novel noncatalytic substrate-selective p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity. J. Immunol. 198, 3296–3306 (2017).
Nichols, C. et al. Mining the PDB for tractable cases where X-ray crystallography combined with fragment screens can be used to systematically design protein–protein inhibitors: two test cases illustrated by IL1β–IL1R and p38α–TAB1 complexes. J. Med. Chem. 63, 7559–7568 (2020).
Lemmens, B. et al. DNA replication determines timing of mitosis by restricting CDK1 and PLK1 activation. Mol. Cell 71, 117–128.e3 (2018).
Thornton, T. M. et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3β inactivation. Science 320, 667–670 (2008).
Cully, M. et al. A role for p38 stress-activated protein kinase in regulation of cell growth via TORC1. Mol. Cell Biol. 30, 481–495 (2010).
Li, L. et al. TLR8-mediated metabolic control of human Treg function: a mechanistic target for cancer immunotherapy. Cell Metab. 29, 103–123.e5 (2019).